Skip to main content
SpringerLink
Log in

Clinical Trials for Erectile Dysfunction in Parkinson’s Disease

  • Protocol
  • First Online:
Clinical Trials In Parkinson's Disease

Part of the book series: Neuromethods ((NM,volume 160))

  • 559 Accesses

Abstract

Impaired sexual function is a very frequent feature of Parkinson’s disease (PD). For example, erectile dysfunction (ED), defined as the inability to attain or maintain penile erection sufficient for satisfactory sexual performance, develops in the majority of men with PD. Management of sexual dysfunction often needs to be multifaceted and may sometimes need to include the partner. The first-line pharmacological treatments for ED are the selective cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 inhibitors (PDE5-I), of which sildenafil has the best evidence, being in clinical use since 1998. Dopamine agonists induce erections in some patients with PD. Results with testosterone are controversial in PD. Clinical trials for treatments of ED in PD remain scarce, and existing studies were limited by small sample size and open-label methodology. Therefore, well-designed double-blind RCTs are required to further understand the efficacy and adverse effect profiles of these treatments in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brown RG, Jahanshahi M, Quinn N, Marsden CD (1990) Sexual function in patients with Parkinson’s disease and their partners. J Neurol Neurosurg Psychiatry 53(6):480–486. https://doi.org/10.1136/jnnp.53.6.480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bronner G (2011) Sexual problems in Parkinson’s disease: the multidimensional nature of the problem and of the intervention. J Neurol Sci 310(1–2):139–143. https://doi.org/10.1016/j.jns.2011.05.050

    Article  PubMed  Google Scholar 

  3. Pfeiffer RF (2012) Autonomic dysfunction in Parkinson’s disease. Expert Rev Neurother 12(6):697–706. https://doi.org/10.1586/ern.12.17

    Article  CAS  PubMed  Google Scholar 

  4. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ (2007) Patient-reported autonomic symptoms in Parkinson disease. Neurology 69(4):333–341. https://doi.org/10.1212/01.wnl.0000266593.50534.e8

    Article  CAS  PubMed  Google Scholar 

  5. Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Ben-Shlomo Y, Wood NW, Grosset DG, Consortium PRC (2016) Autonomic dysfunction in early Parkinson’s disease: results from the United Kingdom tracking Parkinson’s study. Mov Disord Clin Pract 4(4):509–516. https://doi.org/10.1002/mdc3.12454

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A (2007) Erectile function and risk of Parkinson’s disease. Am J Epidemiol 166(12):1446–1450. https://doi.org/10.1093/aje/kwm246

    Article  PubMed  PubMed Central  Google Scholar 

  7. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14(1):57–64. https://doi.org/10.1016/s1474-4422(14)70287-x

    Article  PubMed  Google Scholar 

  8. Yang Y, Liu H, Lin T, Kuo Y, Hsieh T (2017) Relationship between erectile dysfunction, comorbidity, and Parkinson’s disease: evidence from a population-based longitudinal study. J Clin Neurol 13(3):250–258. https://doi.org/10.3988/jcn.2017.13.3.250

    Article  PubMed  PubMed Central  Google Scholar 

  9. De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT (2017) Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol 74(8):970–976. https://doi.org/10.1001/jamaneurol.2017.1125

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bronner G, Korczyn AD (2017) The role of sex therapy in the management of patients with Parkinson’s disease. Mov Disord Clin Pract 5(1):6–13. https://doi.org/10.1002/mdc3.12561

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lim S-Y, Evans AH, Miyasaki JM (2008) Impulse control and related disorders in Parkinson’s disease. Ann N Y Acad Sci 1142(1):85–107. https://doi.org/10.1196/annals.1444.006

    Article  CAS  PubMed  Google Scholar 

  12. Codling D, Shaw P, David AS (2015) Hypersexuality in Parkinson’s disease: systematic review and report of 7 new cases. Mov Disord Clin Pract 2(2):116–126. https://doi.org/10.1002/mdc3.12155

    Article  PubMed  PubMed Central  Google Scholar 

  13. Jitkritsadakul O, Jagota P, Bhidayasiri R (2015) Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 21(1):61–67. https://doi.org/10.1016/j.parkreldis.2014.11.003

    Article  PubMed  Google Scholar 

  14. Peak TC, Yafi FA, Sangkum P, Hellstrom WJG (2015) Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs 20(2):263–275. https://doi.org/10.1517/14728214.2015.1021682

    Article  CAS  PubMed  Google Scholar 

  15. Mobley DF, Khera M, Baum N (2017) Recent advances in the treatment of erectile dysfunction. Postgrad Med J 93(1105):679–685. https://doi.org/10.1136/postgradmedj-2016-134073

    Article  CAS  PubMed  Google Scholar 

  16. Lim S-Y, Fox SH, Lang AE (2009) Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66(2). https://doi.org/10.1001/archneurol.2008.561

  17. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3(1). https://doi.org/10.1038/nrdp.2017.13

  18. Basson R (1996) Sexuality and Parkinson’s disease. Parkinsonism Relat Disord 2(4):177–185. https://doi.org/10.1016/s1353-8020(96)00020-x

    Article  CAS  PubMed  Google Scholar 

  19. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S (2006) Erectile dysfunction in Parkinson’s disease. Urology 67(3):447–451. https://doi.org/10.1016/j.urology.2005.10.017

    Article  CAS  PubMed  Google Scholar 

  20. Bronner G, Royter V, Korczyn AD, Giladi NIR (2004) Sexual dysfunction in Parkinson’s disease. J Sex Marital Ther 30(2):95–105. https://doi.org/10.1080/00926230490258893

    Article  PubMed  Google Scholar 

  21. Cleeves L, Findley LJ (1987) Bromocriptine induced impotence in Parkinson’s disease. Br Med J (Clin Res Ed) 295(6594):367–368. https://doi.org/10.1136/bmj.295.6594.367-a

    Article  CAS  Google Scholar 

  22. Fox SH, Katzenschlager R, Lim S-Y, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266. https://doi.org/10.1002/mds.27372

    Article  CAS  PubMed  Google Scholar 

  23. Lim S-Y, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu Y-R, Shang H-F, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan E-K, Lang AE (2019) Parkinson’s disease in the Western Pacific region. Lancet Neurol 18(9):865–879. https://doi.org/10.1016/s1474-4422(19)30195-4

    Article  PubMed  Google Scholar 

  24. Francis ME, Kusek JW, Nyberg LM, Eggers PW (2007) The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J Urol 178(2):591–596. https://doi.org/10.1016/j.juro.2007.03.127

    Article  PubMed  Google Scholar 

  25. Simonsen U, Comerma-Steffensen S, Andersson K-E (2016) Modulation of dopaminergic pathways to treat erectile dysfunction. Basic Clin Pharmacol Toxicol 119:63–74. https://doi.org/10.1111/bcpt.12653

    Article  CAS  PubMed  Google Scholar 

  26. Shin YS, Karna KK, Choi BR, Park JK (2019) Finasteride and erectile dysfunction in patients with benign prostatic hyperplasia or male androgenetic alopecia. World J Mens Health 37(2):157–165. https://doi.org/10.5534/wjmh.180029

    Article  PubMed  Google Scholar 

  27. Kouidrat Y, Pizzol D, Cosco T, Thompson T, Carnaghi M, Bertoldo A, Solmi M, Stubbs B, Veronese N (2017) High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med 34(9):1185–1192. https://doi.org/10.1111/dme.13403

    Article  CAS  PubMed  Google Scholar 

  28. Bronner G (2009) Practical strategies for the management of sexual problems in Parkinson’s disease. Parkinsonism Relat Disord 15:S96–S100. https://doi.org/10.1016/s1353-8020(09)70791-6

    Article  PubMed  Google Scholar 

  29. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C, The collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine C (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 34(2):180–198. https://doi.org/10.1002/mds.27602

    Article  PubMed  PubMed Central  Google Scholar 

  30. Palma J-A, Kaufmann H (2018) Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 33(3):372–390. https://doi.org/10.1002/mds.27344

    Article  PubMed  PubMed Central  Google Scholar 

  31. Briganti A, Salonia A, Gallina A, Saccà A, Montorsi P, Rigatti P, Montorsi F (2005) Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2(5):239–247. https://doi.org/10.1038/ncpuro0186

    Article  CAS  PubMed  Google Scholar 

  32. Moore RA, Edwards JE, McQuay HJ (2002) Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2:6–6. https://doi.org/10.1186/1471-2490-2-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Müller A, Smith L, Parker M, Mulhall JP (2007) Analysis of the efficacy and safety of sildenafil citrate in the geriatric population. BJU Int 100(1):117–121. https://doi.org/10.1111/j.1464-410x.2007.06915.x

    Article  PubMed  Google Scholar 

  34. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71(3):371–374. https://doi.org/10.1136/jnnp.71.3.371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zesiewicz TA, Helal M, Hauser RA (2000) Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord 15(2):305–308. https://doi.org/10.1002/1531-8257(200003)15:2<305::aid-mds1015>3.0.co;2-w

    Article  CAS  PubMed  Google Scholar 

  36. Bernard BA, Metman LV, Levine L, Ouyang B, Leurgans S, Goetz CG (2016) Sildenafil in the treatment of erectile dysfunction in Parkinson’s disease. Mov Disord Clin Pract 4(3):412–415. https://doi.org/10.1002/mdc3.12456

    Article  PubMed  PubMed Central  Google Scholar 

  37. Bronner G, Vodušek DB (2011) Management of sexual dysfunction in Parkinson's disease. Ther Adv Neurol Disord 4(6):375–383. https://doi.org/10.1177/1756285611411504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Chrysant SG (2013) Effectiveness and safety of Phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 15(5):475–483. https://doi.org/10.1007/s11906-013-0377-9

    Article  CAS  PubMed  Google Scholar 

  39. Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (2018) Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart 104(15):1244–1250. https://doi.org/10.1136/heartjnl-2017-312865

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Giammusso B, Raffaele R, Vecchio I, Giammona G, Ruggieri M, Nicoletti G, Malaguarnera M, Rampello L, Nicoletti F (2002) Sildenafil in the treatment of erectile dysfunction in elderly depressed patientswith idiopathic Parkinson’s disease. Arch Gerontol Geriatr 35:157–163. https://doi.org/10.1016/s0167-4943(02)00124-3

    Article  Google Scholar 

  41. Raffaele R (2002) Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur Urol 41(4):382–386. https://doi.org/10.1016/s0302-2838(02)00054-4

    Article  CAS  PubMed  Google Scholar 

  42. Fine J, Lang AE (1999) Dose-induced penile erections in response to ropinirole therapy for Parkinson’s disease. Mov Disord 14(4):701–702. https://doi.org/10.1002/1531-8257(199907)14:4<701::aid-mds1026>3.0.co;2-r

    Article  CAS  PubMed  Google Scholar 

  43. Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T (2011) Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsons Dis 2011:924605–924605. https://doi.org/10.4061/2011/924605

    Article  PubMed  PubMed Central  Google Scholar 

  44. Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O (2013) Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs 18(1):39–53. https://doi.org/10.1517/14728214.2013.766168

    Article  CAS  PubMed  Google Scholar 

  45. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS, Testosterone Trials I (2016) Effects of testosterone treatment in older men. The New England journal of medicine 374(7):611–624. https://doi.org/10.1056/NEJMoa1506119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Yeap BB, Page ST, Grossmann M (2018) Testosterone treatment in older men: clinical implications and unresolved questions from the testosterone trials. Lancet Diabet Endocrinol 6(8):659–672. https://doi.org/10.1016/s2213-8587(17)30416-3

    Article  CAS  Google Scholar 

  47. Okun MS (2002) Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency. Arch Neurol 59(5):807. https://doi.org/10.1001/archneur.59.5.807

    Article  PubMed  Google Scholar 

  48. Okun MS, Walter BL, McDonald WM, Tenover JL, Green J, Juncos JL, DeLong MR (2002) Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol 59(11):1750. https://doi.org/10.1001/archneur.59.11.1750

    Article  PubMed  Google Scholar 

  49. Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G (2006) Testosterone therapy in men with Parkinson disease. Arch Neurol 63(5):729. https://doi.org/10.1001/archneur.63.5.729

    Article  PubMed  Google Scholar 

  50. Coon EA, Cutsforth-Gregory JK, Benarroch EE (2018) Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord 33(3):349–358. https://doi.org/10.1002/mds.27186

    Article  PubMed  Google Scholar 

  51. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner E-M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80. https://doi.org/10.1002/mds.23884

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

    Shen-Yang Lim & Ai Huey Tan

  2. The Mah Pooi Soo and Tan Chin Nam Centre for Parkinson’s and Related Disorders, University of Malaya, Kuala Lumpur, Malaysia

    Shen-Yang Lim & Ai Huey Tan

  3. Neurology Laboratory, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

    Shen-Yang Lim

  4. Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

    Mathis Grossmann

  5. Department of Endocrinology, Austin Health, Melbourne, VIC, Australia

    Mathis Grossmann

Authors
  1. Shen-Yang Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ai Huey Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mathis Grossmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Research Council (CAECHIS-UAI), Buenos Aires, Argentina

    Santiago Perez-Lloret

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Lim, SY., Tan, A.H., Grossmann, M. (2021). Clinical Trials for Erectile Dysfunction in Parkinson’s Disease. In: Perez-Lloret, S. (eds) Clinical Trials In Parkinson's Disease. Neuromethods, vol 160. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0912-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0912-5_14

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0911-8

  • Online ISBN: 978-1-0716-0912-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation